Minerva Neurosciences, Inc.
Join Class Action »
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Minerva Neurosciences, Inc. (NASDAQ: NERV) from May 15, 2017 through November 30, 2020 (the “Class Period”). The lawsuit seeks to recover damages for Minerva Neurosciences, Inc. investors under the federal securities laws.
If you bought Minerva Neurosciences, Inc. securities between May 15, 2017 through November 30, 2020, and would like to join the action, please click “Join This Class Action,” above.
SHAREHOLDER ALERT: Zhang Investor Law Announces the Filing of a Securities Class Action Lawsuit Against Minerva Neurosciences, Inc. – NERV
New York, N.Y., December 11, 2020. Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017 and November 30, 2020, inclusive (the “Class Period”).
To join the NERV class action, go to http://zhanginvestorlaw.com/cases/minerva-neurosciences-inc/ call Sophie Zhang, Esq. toll-free at 800-991-3756 or email email@example.com for information on the class action.
Lead plaintiff status is not required to seek compensation. You may retain counsel of your choice. You may remain an absent class member and take no action at this time.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that (1) the truth about the feedback received from the FDA concerning the “end-of-Phase 2” meeting; (2) the Phase 2b study did not use the commercial formulation of roluperidone and was conducted solely outside of the United States; (3) the failure of the Phase 3 study to meet its primary and key secondary endpoints rendered that study incapable of supporting substantial evidence of effectiveness; (4) the Company’s plan to use the combination of the Phase 2b and Phase 3 studies would be “highly unlikely” to support the submission of an NDA; (5) reliance on these two trials in the submission of an NDA would lead to “substantial review issues” because the trials were inadequate and not well-controlled; and (6) as a result, the Company’s public statements were materially false and misleading at all relevant times.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 8, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://zhanginvestorlaw.com/cases/minerva-neurosciences-inc/ or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. of Zhang Investor Law toll free at 800-991-3756 or via e-mail at firstname.lastname@example.org.
Zhang Investor Law represents investors worldwide.